RMAX vs SRPT · P/E 480, rev $307.7M vs rev $1.90B
Re Max Holding (RMAX) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Re Max Holding (RMAX) is a real estate services company listed on NYSE.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported RMAX revenue for 2024-12-31 was $307.7M. Net income was $8.1M. Revenue was down 5.5% from 2023-12-31 to 2024-12-31. RMAX currently screens at market cap $527.7M and trailing P/E 479.5.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
RMAX currently screens at market cap $527.7M and trailing P/E 479.5. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the RMAX and SRPT stock pages for the full models.
Not investment advice.